- Discuss how today’s pipeline and technologies are reshaping our biomanufacturing
- Review case studies and strategies for rapid manufacturing scale up for leading products
- Focus on the criticality of investing in people and robust strategies to support the workforce and culture
- Show opportunities that allow for successful navigation in the future of manufacturing, including leveraging legacy and culture as drivers of change
SVP, Global Biologics & Sterile Operations
Karin is SVP, Global Biologics and Sterile Operations at Merck Pharmaceutical where she holds operational responsibility for manufacturing Keytruda and Gardasil in addition to other in-line and pipeline products. She has over 22 years experience in the pharmaceutical industry, beginning her career in pharma with Bristol-Myers Squibb in their global supply chain organization. Since leaving BMS, she has held global operations roles in Becton Dickenson, Catalent Pharmaceuticals and Teva Pharmaceutical. During her career, Karin has led global operations with as many as 24 sites and 7,000+ employees across Canada, US and Europe. Through 22+ years, she has gained experience in many technologies, from radiopharmaceuticals to oral solid dose, but always finds her way back to biologics and sterile operations. Prior to joining the pharma industry, she held supply chain roles at Daimler Benz and the U.S. military in her home town of Berlin, Germany. She holds a BA in Political Science & International Relations from Rutgers University and currently resides in New Jersey with her family.